Symbols / DNA Stock $7.85 +0.38% Ginkgo Bioworks Holdings, Inc.

Healthcare • Biotechnology • United States • NYQ
DNA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jason Kelly Ph.D.
Exch · Country NYQ · United States
Market Cap 486.11M
Enterprise Value 474.19M
Income -312.76M
Sales 170.16M
FCF (ttm) -72.88M
Book/sh 8.74
Cash/sh 7.26
Employees 485
Insider 10d —
IPO Apr 19, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.16
PEG —
P/S 2.86
P/B 0.90
P/C —
EV/EBITDA -1.77
EV/Sales 2.79
Quick Ratio 4.66
Current Ratio 4.92
Debt/Eq 86.49
LT Debt/Eq —
EPS (ttm) -5.64
EPS next Y -3.63
EPS Growth —
Revenue Growth -23.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-02-26
ROA -15.42%
ROE -51.08%
ROIC —
Gross Margin 72.39%
Oper. Margin -209.74%
Profit Margin -183.81%
Shs Outstand 49.94M
Shs Float 41.14M
Insider Own 4.06%
Instit Own 73.08%
Short Float 12.52%
Short Ratio 5.42
Short Interest 6.10M
52W High 17.58
vs 52W High -55.35%
52W Low 5.37
vs 52W Low 46.18%
Beta 1.57
Impl. Vol. 1.56%
Rel Volume 0.45
Avg Volume 1.20M
Volume 536.36K
Target (mean) $8.67
Tgt Median $9.00
Tgt Low $5.00
Tgt High $12.00
# Analysts 3
Recom Hold
Prev Close $7.82
Price $7.85
Change 0.38%
About

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.67
Mean price target
2. Current target
$7.85
Latest analyst target
3. DCF / Fair value
$-26.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.85
Low
$5.00
High
$12.00
Mean
$8.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-12 main BTIG Sell → Sell $5
2026-01-08 main TD Cowen Buy → Buy $12
2025-08-25 main BTIG Sell → Sell $9
2024-09-20 main TD Cowen Buy → Buy $10
2024-08-23 main BTIG Sell → Sell $7
2024-07-09 main Goldman Sachs Sell → Sell $0
2024-06-26 main BTIG Sell → Sell $0
2024-05-15 down BTIG Neutral → Sell —
2024-05-15 main Morgan Stanley Equal-Weight → Equal-Weight $1
2024-05-10 down William Blair Market Perform → Underperform —
2024-03-01 main TD Cowen Outperform → Outperform $3
2024-01-23 main Goldman Sachs Sell → Sell $1
2024-01-22 main Goldman Sachs Sell → Sell $1
2023-11-15 down Raymond James Outperform → Market Perform $3
2023-11-14 down Raymond James Outperform → Market Perform $3
2023-11-09 down BTIG Buy → Neutral —
2023-06-05 main Goldman Sachs Sell → Sell $1
2023-06-02 down Goldman Sachs Neutral → Sell $1
2023-05-11 down William Blair Outperform → Market Perform —
2022-11-29 init Berenberg — → Buy $6
News
RSS: Latest DNA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-17 COEN STEVEN P. Chief Financial Officer — 324 $7.95 $2,576
2026-04-16 COEN STEVEN P. Chief Financial Officer — 743 — —
2026-04-13 COEN STEVEN P. Chief Financial Officer — 33,171 $6.41 $212,759
2026-04-10 CANTON BARTHOLOMEW Beneficial Owner of more than 10% of a Class of Security — 124,727 $6.43 $802,494
2026-04-10 COEN STEVEN P. Chief Financial Officer — 73,921 — —
2026-04-10 SHETTY RESHMA PADMINI President — 124,727 $6.43 $802,494
2026-04-09 CANTON BARTHOLOMEW Beneficial Owner of more than 10% of a Class of Security — 26,271 $6.40 $175,067
2026-04-09 CANTON BARTHOLOMEW Beneficial Owner of more than 10% of a Class of Security — 251,786 — —
2026-04-09 KELLY JASON R Chief Executive Officer — 206,782 $6.40 $1,374,493
2026-04-09 SHETTY RESHMA PADMINI President — 26,271 $6.40 $175,067
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
170.16
-25.06%
227.04
-9.71%
251.46
-47.36%
477.71
Operating Revenue
170.16
-25.06%
227.04
-9.71%
251.46
-47.36%
477.71
Cost Of Revenue
46.97
+5.44%
44.55
-17.51%
54.01
-73.55%
204.22
Reconciled Cost Of Revenue
46.97
+5.44%
44.55
-17.51%
54.01
-73.55%
204.22
Gross Profit
123.18
-32.50%
182.50
-7.57%
197.45
-27.80%
273.49
Operating Expense
427.06
-36.28%
670.22
-30.59%
965.65
-61.10%
2,482.44
Research And Development
243.77
-42.51%
424.06
-26.96%
580.62
-44.84%
1,052.64
Selling General And Administration
183.29
-25.54%
246.16
-36.07%
385.02
-73.07%
1,429.80
General And Administrative Expense
183.29
-25.54%
246.16
-36.07%
385.02
-73.07%
1,429.80
Other Gand A
183.29
-25.54%
246.16
-36.07%
385.02
-73.07%
1,429.80
Total Expenses
474.04
-33.68%
714.77
-29.90%
1,019.65
-62.05%
2,686.66
Operating Income
-303.88
+37.69%
-487.73
+36.51%
-768.20
+65.22%
-2,208.95
Total Operating Income As Reported
-315.28
+43.68%
-559.76
+35.24%
-864.41
+60.87%
-2,208.95
EBITDA
-254.61
+47.44%
-484.39
+41.10%
-822.34
+60.44%
-2,078.74
Normalized EBITDA
-226.80
+40.66%
-382.23
+39.71%
-633.97
+70.95%
-2,182.26
Reconciled Depreciation
58.99
-6.39%
63.02
-10.62%
70.51
+65.70%
42.55
EBIT
-313.60
+42.71%
-547.41
+38.69%
-892.85
+57.91%
-2,121.29
Total Unusual Items
-27.81
+72.78%
-102.17
+45.76%
-188.37
-281.96%
103.52
Total Unusual Items Excluding Goodwill
-27.81
+72.78%
-102.17
+45.76%
-188.37
-281.96%
103.52
Special Income Charges
-11.40
+85.58%
-79.04
+43.02%
-138.71
-534.98%
31.89
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
0.00
-100.00%
47.86
-50.26%
96.21
0.00
Restructuring And Mergern Acquisition
11.40
-52.85%
24.17
0.00
0.00
Net Income
-312.76
+42.83%
-547.03
+38.73%
-892.87
+57.58%
-2,104.93
Pretax Income
-313.60
+42.72%
-547.51
+38.68%
-892.94
+57.91%
-2,121.40
Net Non Operating Interest Income Expense
22.62
-41.28%
38.52
-32.57%
57.12
+183.41%
20.16
Interest Expense Non Operating
0.00
-100.00%
0.09
+1.08%
0.09
-12.26%
0.11
Net Interest Income
22.62
-41.28%
38.52
-32.57%
57.12
+183.41%
20.16
Interest Expense
0.00
-100.00%
0.09
+1.08%
0.09
-12.26%
0.11
Interest Income Non Operating
22.62
-41.43%
38.61
-32.52%
57.22
+182.39%
20.26
Interest Income
22.62
-41.43%
38.61
-32.52%
57.22
+182.39%
20.26
Other Income Expense
-32.34
+67.10%
-98.30
+45.95%
-181.87
-369.85%
67.40
Other Non Operating Income Expenses
-4.53
-216.98%
3.87
-57.65%
9.14
+19.70%
7.63
Gain On Sale Of Security
-16.41
+29.04%
-23.13
+53.43%
-49.66
-169.32%
71.64
Gain On Sale Of Business
0.00
+100.00%
-7.01
+83.50%
-42.50
-233.28%
31.89
Tax Provision
-0.84
-74.74%
-0.48
-574.65%
-0.07
+99.53%
-15.03
Tax Rate For Calcs
0.00
+200.00%
0.00
+1150.00%
0.00
-98.87%
0.00
Tax Effect Of Unusual Items
-0.08
+18.34%
-0.10
-582.13%
-0.01
-102.04%
0.73
Net Income Including Noncontrolling Interests
-312.76
+42.83%
-547.03
+38.73%
-892.87
+57.61%
-2,106.37
Net Income From Continuing Operation Net Minority Interest
-312.76
+42.83%
-547.03
+38.73%
-892.87
+57.58%
-2,104.93
Net Income From Continuing And Discontinued Operation
-312.76
+42.83%
-547.03
+38.73%
-892.87
+57.58%
-2,104.93
Net Income Continuous Operations
-312.76
+42.83%
-547.03
+38.73%
-892.87
+57.61%
-2,106.37
Minority Interests
—
0.00
0.00
-100.00%
1.44
Normalized Income
-285.04
+35.94%
-444.96
+36.84%
-704.51
+68.09%
-2,207.72
Net Income Common Stockholders
-312.76
+42.83%
-547.03
+38.73%
-892.87
+57.58%
-2,104.93
Otherunder Preferred Stock Dividend
—
—
0.00
-100.00%
3.14
Diluted EPS
-5.64
+46.49%
-10.54
+42.62%
-18.37
+63.26%
-50.00
Basic EPS
-5.64
+46.49%
-10.54
+42.62%
-18.37
+63.26%
-50.00
Basic Average Shares
55.46
+6.87%
51.89
+6.76%
48.61
+15.80%
41.98
Diluted Average Shares
55.46
+6.87%
51.89
+6.76%
48.61
+15.75%
42.00
Diluted NI Availto Com Stockholders
-312.76
+42.83%
-547.03
+38.73%
-892.87
+57.58%
-2,104.93
Earnings From Equity Interest
0.00
0.00
+100.00%
-2.63
+93.98%
-43.76
Line Item Trend 2023-12-31 2021-12-31
Total Assets
1,665.34
—
Current Assets
1,001.75
—
Cash Cash Equivalents And Short Term Investments
944.07
—
Cash And Cash Equivalents
944.07
—
Other Short Term Investments
—
—
Receivables
17.90
—
Accounts Receivable
17.16
—
Gross Accounts Receivable
18.90
—
Allowance For Doubtful Accounts Receivable
-1.00
—
Other Receivables
1.55
-29.66%
2.20
Loans Receivable
—
11.56
Inventory
0.05
-98.63%
3.36
Raw Materials
—
0.06
Work In Process
—
0.05
Finished Goods
—
3.26
Prepaid Assets
20.74
+8.69%
19.08
Restricted Cash
4.79
0.00
Other Current Assets
39.78
—
Total Non Current Assets
663.59
—
Net PPE
394.99
—
Gross PPE
515.71
—
Accumulated Depreciation
-120.72
—
Properties
0.00
—
Land And Improvements
6.06
—
Buildings And Improvements
47.03
—
Machinery Furniture Equipment
21.24
—
Construction In Progress
15.83
—
Other Properties
353.99
—
Leases
71.56
—
Goodwill And Other Intangible Assets
131.98
—
Goodwill
49.24
+131.03%
21.31
Other Intangible Assets
82.74
—
Investments And Advances
77.91
—
Long Term Equity Investment
0.00
-100.00%
13.19
Other Investments
23.90
—
Other Non Current Assets
58.05
—
Total Liabilities Net Minority Interest
568.19
—
Current Liabilities
163.86
—
Payables And Accrued Expenses
43.51
—
Payables
9.32
—
Accounts Payable
9.32
—
Current Accrued Expenses
34.19
—
Pensionand Other Post Retirement Benefit Plans Current
15.68
—
Current Debt And Capital Lease Obligation
17.47
—
Current Capital Lease Obligation
17.47
—
Current Deferred Liabilities
48.49
—
Current Deferred Revenue
48.49
—
Other Current Liabilities
38.70
—
Total Non Current Liabilities Net Minority Interest
404.33
—
Long Term Debt And Capital Lease Obligation
221.84
—
Long Term Capital Lease Obligation
221.84
—
Non Current Deferred Liabilities
158.06
—
Non Current Deferred Revenue
158.06
—
Other Non Current Liabilities
24.43
—
Stockholders Equity
1,097.15
—
Common Stock Equity
1,097.15
—
Capital Stock
0.01
—
Common Stock
0.01
—
Preferred Stock
0.00
—
Share Issued
50.03
—
Ordinary Shares Number
50.03
—
Treasury Shares Number
0.00
-100.00%
79.60
Additional Paid In Capital
6,386.19
—
Retained Earnings
-5,290.53
—
Gains Losses Not Affecting Retained Earnings
1.48
—
Minority Interest
0.00
-100.00%
62.01
Other Equity Adjustments
1.48
—
Total Equity Gross Minority Interest
1,097.15
—
Total Capitalization
1,097.15
—
Working Capital
837.89
—
Invested Capital
1,097.15
—
Total Debt
239.31
—
Capital Lease Obligations
239.31
—
Net Tangible Assets
965.17
—
Tangible Book Value
965.17
—
Available For Sale Securities
54.01
—
Derivative Product Liabilities
5.70
-95.80%
135.84
Duefrom Related Parties Current
0.74
—
Financial Assets
0.65
—
Inventories Adjustments Allowances
—
-0.02
Investmentin Financial Assets
54.01
—
Non Current Note Receivables
13.60
0.00
Notes Receivable
12.29
+6.35%
11.56
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-171.06
+46.47%
-319.58
-8.15%
-295.50
-17.17%
-252.20
Cash Flow From Continuing Operating Activities
-171.06
+46.47%
-319.58
-8.15%
-295.50
-17.17%
-252.20
Net Income From Continuing Operations
-312.76
+42.83%
-547.03
+38.73%
-892.87
+57.61%
-2,106.37
Depreciation Amortization Depletion
58.99
-6.39%
63.02
-10.62%
70.51
+65.70%
42.55
Depreciation
—
—
71.55
+61.07%
44.42
Depreciation And Amortization
58.99
-6.39%
63.02
-10.62%
70.51
+65.70%
42.55
Other Non Cash Items
33.60
-36.87%
53.23
+4.57%
50.90
+574.28%
-10.73
Stock Based Compensation
81.55
-27.41%
112.34
-51.13%
229.88
-88.09%
1,930.64
Asset Impairment Charge
0.00
-100.00%
58.48
-51.83%
121.40
0.00
Deferred Tax
-1.36
-45.73%
-0.94
-16.85%
-0.80
+94.52%
-14.61
Deferred Income Tax
-1.36
-45.73%
-0.94
-16.85%
-0.80
+94.52%
-14.61
Operating Gains Losses
16.41
-47.03%
30.98
-67.60%
95.64
+268.76%
-56.67
Gain Loss On Investment Securities
16.41
-29.04%
23.13
-53.43%
49.66
+169.32%
-71.64
Gain Loss On Sale Of PPE
0.00
-100.00%
0.84
+0.24%
0.84
-72.76%
3.09
Change In Working Capital
-44.09
+50.83%
-89.67
-400.53%
29.84
+180.63%
-37.01
Change In Receivables
-1.47
+68.83%
-4.72
-109.44%
50.07
-9.01%
55.02
Changes In Account Receivables
-1.47
+68.83%
-4.72
-109.44%
50.07
-9.01%
55.02
Change In Inventory
—
—
—
0.16
Change In Prepaid Assets
-5.25
-152.03%
10.09
-3.70%
10.47
+222.88%
-8.52
Change In Payables And Accrued Expense
7.38
+120.70%
-35.67
-326.95%
15.72
+131.13%
-50.48
Change In Accrued Expense
10.38
+125.66%
-40.44
-339.29%
16.90
+142.63%
-39.64
Change In Payable
-2.99
-162.71%
4.77
+503.30%
-1.18
+89.09%
-10.84
Change In Account Payable
-2.99
-162.71%
4.77
+503.30%
-1.18
+89.09%
-10.84
Change In Other Working Capital
-32.39
+52.81%
-68.64
-91.12%
-35.92
+1.37%
-36.42
Change In Other Current Assets
4.11
-81.38%
22.07
+86.31%
11.85
-16.31%
14.15
Change In Other Current Liabilities
-16.47
-28.79%
-12.79
+42.78%
-22.35
-107.68%
-10.76
Investing Cash Flow
-240.29
-286.09%
-62.24
+22.87%
-80.69
-19.73%
-67.39
Cash Flow From Continuing Investing Activities
-240.29
-286.09%
-62.24
+22.87%
-80.69
-19.73%
-67.39
Net PPE Purchase And Sale
-7.09
+88.54%
-61.89
-70.16%
-36.37
+30.41%
-52.27
Purchase Of PPE
-7.67
+87.74%
-62.54
-53.28%
-40.80
+21.94%
-52.27
Sale Of PPE
0.57
-11.42%
0.65
-85.37%
4.43
0.00
Capital Expenditure
-7.67
+87.74%
-62.54
-53.28%
-40.80
+21.94%
-52.27
Net Investment Purchase And Sale
-233.25
-5261.50%
4.52
0.00
+100.00%
-3.69
Purchase Of Investment
-418.63
0.00
0.00
+100.00%
-3.69
Sale Of Investment
185.38
+4002.28%
4.52
0.00
0.00
Net Business Purchase And Sale
0.00
+100.00%
-5.40
+87.44%
-42.98
-261.30%
26.65
Purchase Of Business
0.00
+100.00%
-5.40
+87.44%
-42.98
+22.87%
-55.72
Gain Loss On Sale Of Business
0.00
-100.00%
7.01
-83.50%
42.50
+233.28%
-31.89
Net Other Investing Changes
0.05
-90.71%
0.54
+140.15%
-1.34
+96.48%
-38.08
Financing Cash Flow
17.77
+1122.14%
-1.74
+45.93%
-3.22
-103.37%
95.34
Cash Flow From Continuing Financing Activities
17.77
+1122.14%
-1.74
+45.93%
-3.22
-103.37%
95.34
Net Issuance Payments Of Debt
-0.35
+60.54%
-0.90
+30.73%
-1.29
-4.69%
-1.24
Repayment Of Debt
-0.35
+60.54%
-0.90
+30.73%
-1.29
-4.69%
-1.24
Long Term Debt Payments
-0.35
+60.54%
-0.90
+30.73%
-1.29
-4.69%
-1.24
Net Long Term Debt Issuance
-0.35
+60.54%
-0.90
+30.73%
-1.29
-4.69%
-1.24
Net Common Stock Issuance
19.47
0.00
0.00
-100.00%
99.30
Common Stock Payments
—
—
0.00
0.00
Repurchase Of Capital Stock
—
—
0.00
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
0.08
-9.68%
0.09
-61.25%
0.24
Net Other Financing Charges
-1.34
-44.71%
-0.93
+54.02%
-2.01
+32.17%
-2.97
Changes In Cash
-393.57
-2.61%
-383.56
-1.09%
-379.41
-69.19%
-224.25
Effect Of Exchange Rate Changes
0.20
+171.53%
-0.28
+52.21%
-0.59
-164.76%
0.91
Beginning Cash Position
605.74
-38.79%
989.58
-27.75%
1,369.58
-14.02%
1,592.93
End Cash Position
212.37
-64.94%
605.74
-38.79%
989.58
-27.75%
1,369.58
Free Cash Flow
-178.72
+53.23%
-382.13
-13.63%
-336.30
-10.45%
-304.47
Interest Paid Supplemental Data
0.00
-87.50%
0.03
-61.45%
0.08
-9.78%
0.09
Income Tax Paid Supplemental Data
0.19
-78.52%
0.89
+33.43%
0.67
0.00
Amortization Of Securities
-3.39
0.00
0.00
—
Common Stock Issuance
19.47
0.00
0.00
-100.00%
99.30
Earnings Losses From Equity Investments
0.00
0.00
-100.00%
2.63
-93.98%
43.76
Issuance Of Capital Stock
19.47
0.00
0.00
-100.00%
99.30
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Sale Of Business
—
—
—
82.37
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category